keyword
MENU ▼
Read by QxMD icon Read
search

Yttrium-90

keyword
https://www.readbyqxmd.com/read/28432387/yttrium-90-radioembolization-for-unresectable-combined-hepatocellular-cholangiocarcinoma
#1
Lauren S Chan, Daniel Y Sze, George A Poultsides, John D Louie, Mohammed A Abdelrazek Mohammed, David S Wang
PURPOSE: Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare mixed cell type primary liver cancer with limited data to guide management. Transarterial radioembolization with yttrium-90 microspheres (RE) is an emerging treatment option for both hepatocellular carcinoma and intrahepatic cholangiocarcinoma. This study explored the safety and efficacy of RE for unresectable cHCC-CC. METHODS: Patients with histopathologically confirmed cHCC-CC treated with RE were retrospectively evaluated...
April 21, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28418940/assessment-of-the-albumin-bilirubin-albi-grade-as-a-prognostic-indicator-for-hepatocellular-carcinoma-patients-treated-with-radioembolization
#2
Bin Gui, Ashley A Weiner, John Nosher, Shou-En Lu, Gretchen M Foltz, Omar Hasan, Seung K Kim, Vyacheslav Gendel, Naganathan B Mani, Darren R Carpizo, Nael E Saad, Timothy J Kennedy, Darryl A Zuckerman, Jeffrey R Olsen, Parag J Parikh, Salma K Jabbour
OBJECTIVE: As the utility of Child-Pugh (C-P) class is limited by the subjectivity of ascites and encephalopathy, we evaluated a previously established objective method, the albumin-bilirubin (ALBI) grade, as a prognosticator for yttrium-90 radioembolization (RE) treatment for patients with hepatocellular carcinoma (HCC). MATERIALS AND METHODS: A total of 117 patients who received RE for HCC from 2 academic centers were reviewed and stratified by ALBI grade, C-P class, and Barcelona Clinic Liver Cancer stage...
April 17, 2017: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28415671/predictors-and-prognosticators-for-survival-with-yttrium-90-radioembolization-therapy-for-unresectable-colorectal-cancer-liver-metastasis
#3
REVIEW
Meaghan S Dendy, Johannes M Ludwig, Hyun S Kim
This critical review aims to explore predictive and prognostic biomarkers of Yttrium-90 (Y90) radioembolization therapy of colorectal liver metastases. A brief overview of established predictive and prognostic molecular and genetic biomarkers in colorectal cancer therapies will be discussed. A review of the literature on imaging modalities, genetic, metabolic and other molecular markers and the subsequent outcomes in post-Y90 treatment will be presented. How these biomarkers and future biomarker research can inform locoregional treatment decisions in the clinical setting of metastatic colorectal cancer lesions of the liver will be explored...
March 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28408731/long-term-outcome-after-liver-transplantation-for-hepatocellular-carcinoma-following-yttrium-90-radioembolization-bridging-treatment
#4
Sonia Radunz, Jürgen Treckmann, Hideo A Baba, Jan Best, Stefan Müller, Jens M Theysohn, Andreas Paul, Tamás Benkö
BACKGROUND Bridging treatments are employed in liver transplant waitlist patients with hepatocellular carcinoma (HCC) because of the risk of tumor progression during the waiting time. Radioembolization is mostly employed in the control of large or multifocal HCCs when other locoregional treatment modalities cannot be applied because of the number or size of lesions. The purpose of this study was to evaluate our experience with the use of radioembolization as a bridge to transplantation and its effect on tumor recurrence and survival after liver transplantation...
April 14, 2017: Annals of Transplantation: Quarterly of the Polish Transplantation Society
https://www.readbyqxmd.com/read/28408533/brachytherapy-with-intratumoral-injections-of-radiometal-labeled-polymers-that-thermo-responsively-self-aggregate-in-tumor-tissues
#5
Kohei Sano, Yuko Kanada, Kengo Kanazaki, Ning Ding, Masahiro Ono, Hideo Saji
Brachytherapy is a type of radiotherapy wherein titanium capsules containing therapeutic radioisotopes are implanted within tumor tissues, enabling high-dose radio-irradiation to tumor tissues around the seeds. Although marked therapeutic effects have been demonstrated, brachytherapy needs complicated implantation technique under general anesthesia and the seeds could migrate to other organs. The aim of this study is to establish a novel brachytherapy using biocompatible, injectable thermo-responsive polymers (polyoxazoline; POZ) labeled with yttrium-90 ((90)Y), which can self-aggregate above a specific transition temperature, resulting in long-term intratumoral retention of radioactivity and therapeutic effect...
April 13, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28407278/prevention-and-treatment-of-complications-of-selective-internal-radiation-therapy-expert-guidance-and-systematic-review
#6
REVIEW
Bruno Sangro, Diego Martínez-Urbistondo, Lourens Bester, Jose I Bilbao, Douglas M Coldwell, Patrick Flamen, Andrew Kennedy, Jens Ricke, Ricky A Sharma
Selective internal radiation therapy (SIRT or radioembolisation) by intraarterial injection of radioactive yttrium-90 ((90) Y)-loaded microspheres is increasingly used for the treatment of patients with liver metastases or primary liver cancer. The high-dose beta-radiation penetrates an average of only 2.5 mm from the source so that its effects are limited to the site of delivery. However the off-target diversion of (90) Y microspheres to tissues other than the tumor may lead to complications. The most prominent ones include: radiation gastritis and gastrointestinal (GI) ulcers, cholecystitis, radiation pneumonitis, and radioembolisation-induced liver disease (REILD)...
April 13, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28365172/segmental-yttrium-90-radioembolization-versus-segmental-chemoembolization-for-localized-hepatocellular-carcinoma-results-of-a-single-center-retrospective-propensity-score-matched-study
#7
Siddharth A Padia, Guy E Johnson, Kathryn J Horton, Christopher R Ingraham, Matthew J Kogut, Sharon Kwan, Sandeep Vaidya, Wayne L Monsky, James O Park, Renuka Bhattacharya, Daniel S Hippe, William P Harris
PURPOSE: To compare segmental radioembolization with segmental chemoembolization for localized, unresectable hepatocellular carcinoma (HCC) not amenable to ablation. MATERIALS AND METHODS: In a single-center, retrospective study (2010-2015), 101 patients with 132 tumors underwent segmental radioembolization, and 77 patients with 103 tumors underwent segmental doxorubicin-based drug-eluting embolic or conventional chemoembolization. Patients receiving chemoembolization had worse performance status (Eastern Cooperative Oncology Group 0, 76% vs 56%; P = ...
March 29, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28357572/safety-and-efficacy-of-y-90-radioembolization-after-prior-major-hepatic-resection
#8
Markus Zimmermann, Maximilian Schulze-Hagen, Martin Liebl, Federico Pedersoli, Fabian Goerg, Tom Florian Ulmer, Alexander Heinzel, Peter Isfort, Christiane Kuhl, Philipp Bruners
PURPOSE: To evaluate the safety and efficacy of yttrium-90 radioembolization (RE) following left or right hepatic lobectomy. MATERIALS AND METHODS: Between 2011 and 2016, 15 patients underwent RE with Y90-resin microspheres following right (8/15) or left (7/15) hepatic lobectomy. In eight patients, the whole liver remnant was treated during a single session, whereas the remaining seven patients received up to 3 selective RE at 1- to 2-month intervals. The administered patient activity was calculated based on the body surface area (BSA) method in all cases...
March 29, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28351831/protocol-for-combined-analysis-of-foxfire-sirflox-and-foxfire-global-randomized-phase-iii-trials-of-chemotherapy-selective-internal-radiation-therapy-as-first-line-treatment-for-patients-with-metastatic-colorectal-cancer
#9
Pradeep S Virdee, Joanna Moschandreas, Val Gebski, Sharon B Love, E Anne Francis, Harpreet S Wasan, Guy van Hazel, Peter Gibbs, Ricky A Sharma
BACKGROUND: In colorectal cancer (CRC), unresectable liver metastases are associated with a poor prognosis. The FOXFIRE (an open-label randomized phase III trial of 5-fluorouracil, oxaliplatin, and folinic acid +/- interventional radioembolization as first-line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer), SIRFLOX (randomized comparative study of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with nonresectable liver metastases from primary colorectal carcinoma), and FOXFIRE-Global (assessment of overall survival of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with nonresectable liver metastases from primary colorectal carcinoma in a randomized clinical study) clinical trials were designed to evaluate the efficacy and safety of combining first-line chemotherapy with selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres, also called transarterial radioembolization...
March 28, 2017: JMIR Research Protocols
https://www.readbyqxmd.com/read/28343412/yttrium-90-microsphere-radioembolization-in-unresectable-intrahepatic-cholangiocarcinoma
#10
Cristina Mosconi, Alberta Cappelli, Salvatore Ascanio, Irene Pettinari, Francesco Modestino, Matteo Renzulli, Maria Cristina Galaverni, Alessandro Cucchetti, Annagiulia Gramenzi, Cinzia Pettinato, Rita Golfieri
Intrahepatic cholangiocarcinoma is increasing in frequency worldwide, but radical surgical treatment is practicable in 30-40% of cases. The median survival without therapy is about 8 months, increased to 12 months in combination with systemic chemotherapy. Therefore, locoregional therapies, such as, radiofrequency ablation or transarterial chemoembolization have been employed. Radioembolization with yttrium-90 microspheres ((90)Y-TARE) is a novel intrarterial treatment which could be included in the armamentarium of treatment options, having shown higher median survival (up to 22 months) and low complication rates...
March 27, 2017: Future Oncology
https://www.readbyqxmd.com/read/28303300/consequences-of-radiopharmaceutical-extravasation-and-therapeutic-interventions-a-systematic-review
#11
REVIEW
Jochem van der Pol, Stefan Vöö, Jan Bucerius, Felix M Mottaghy
PURPOSE: Radiopharmaceutical extravasation can potentially lead to severe soft tissue damage, but little is known about incidence, medical consequences, possible interventions, and effectiveness of these. The aims of this study are to estimate the incidence of extravasation of diagnostic and therapeutic radiopharmaceuticals, to evaluate medical consequences, and to evaluate medical treatment applied subsequently to those incidents. METHODS: A sensitive and elaborate literature search was performed in Embase and PubMed using the keywords "misadministration", "extravasation", "paravascular infiltration", combined with "tracer", "radionuclide", "radiopharmaceutical", and a list of keywords referring to clinically used tracers (i...
March 16, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28300366/internal-dosimetry-for-radioembolization-therapy-with-yttrium-90-microspheres
#12
Maryam Fallahpoor, Mehrshad Abbasi, Ali Asghar Parach, Faraz Kalantari
The absorbed doses in the liver and adjacent viscera in Yttrium-90 radioembolization therapy for metastatic liver lesions are not well-documented. We sought for a clinically practical way to determine the dosimetry of this advent treatment. Six different female XCAT BMIs and seven different male XCAT BMIs were generated. Using Monte Carlo GATE code simulation, the total of 100MBq (90) Y was deposited uniformly in the source organ, liver. Self-irradiation and absorbed doses in lung, kidney and bone marrow were calculated...
March 2017: Journal of Applied Clinical Medical Physics
https://www.readbyqxmd.com/read/28291008/the-efficacy-of-yttrium-90-radiosynovectomy-in-patients-with-camptodactyly-arthropathy-coxa-vara-pericarditis-syndrome
#13
Sulaiman Mohammed Al-Mayouf, Nora Almutairi, Khalid Alismail
OBJECTIVE: Camptodactyly-arthropathy-coxa-vara-pericarditis (CACP) syndrome is an autosomal recessive disorder caused by mutations in PRG4 gene that encodes for proteoglycan 4, the main lubricant for joints and tendon surfaces. It is a non-inflammatory arthropathy, characterized by joint effusions and synovial hypertrophy. So far, there is no effective treatment for this disorder. To evaluate the effectiveness of yttrium-90 radiosynovectomy in arthropathy of patients with CACP syndrome...
February 5, 2017: Molecular Imaging and Radionuclide Therapy
https://www.readbyqxmd.com/read/28267593/phase-ii-study-of-yttrium-90-ibritumomab-tiuxetan-plus-high-dose-bcnu-etoposide-cytarabine-and-melphalan-for-non-hodgkin-lymphoma-the-role-of-histology
#14
Amrita Y Krishnan, Joycelynne Palmer, Auayporn P Nademanee, Robert Chen, Leslie L Popplewell, Ni-Chun Tsai, James F Sanchez, Jennifer Simpson, Ricardo Spielberger, Dave Yamauchi, Stephen J Forman
Standard-dose (90)yttrium-ibritumomab tiuxetan (.4 mci/kg) together with high-dose BEAM (BCNU, etoposide, cytarabine, and melphalan) (Z-BEAM) has been shown to be a well-tolerated autologous hematopoietic stem cell transplantation preparative regimen for non-Hodgkin lymphoma. We report the outcomes of a single-center, single-arm phase II trial of Z-BEAM conditioning in high-risk CD20(+) non-Hodgkin lymphoma histologic strata: diffuse large B cell (DLBCL), mantle cell, follicular, and transformed. Robust overall survival and notably low nonrelapse mortality rates (...
March 4, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28261595/commentary-on-the-article-entitled-hepatocellular-carcinoma-with-macrovascular-invasion-treated-with-yttrium-90-radioembolization-prior-to-transplantation
#15
Wan Yee Lau
No abstract text is available yet for this article.
February 2017: Hepatobiliary Surgery and Nutrition
https://www.readbyqxmd.com/read/28261594/hepatocellular-carcinoma-with-macrovascular-invasion-treated-with-yttrium-90-radioembolization-prior-to-transplantation
#16
Giovanni Battista Levi Sandri, Giuseppe Maria Ettorre, Marco Colasanti, Edoardo De Werra, Gianluca Mascianà, Daniele Ferraro, Giovanni Tortorelli, Rosa Sciuto, Pierleone Lucatelli, Giuseppe Pizzi, Ubaldo Visco-Comandini, Giovanni Vennarecci
BACKGROUND: Yttrium-90 microspheres radioembolization (Y90-RE) has shown to be an effective and safe treatment of primary liver tumors. According to the staging system of the Barcelona Clinic Liver Cancer (BCLC), patients with macrovascular invasion are staged as BCLC-C. This paper comprises a presentation of the results following application of the procedure. METHODS: From January 2002 to December 2015, 367 patients were transplanted at the San Camillo Hospital Center...
February 2017: Hepatobiliary Surgery and Nutrition
https://www.readbyqxmd.com/read/28261591/intra-arterial-embolotherapy-for-intrahepatic-cholangiocarcinoma-update-and-future-prospects
#17
REVIEW
Lynn Jeanette Savic, Julius Chapiro, Jean-François H Geschwind
Intrahepatic cholangiocarcinoma (ICC) is a rare disease and carries a poor prognosis with surgery remaining the only curative treatment option. However, due to the late presentation of symptoms and close proximity of the tumors to central hepatic structures, only about 30% of patients are classified eligible to resection. As for palliative approaches, ICC constitutes a possible indication for loco-regional therapies (LRT). As such, intra-arterial therapies (IAT) are reported to be feasible, safe and effective in inducing tumor response in unresectable ICC...
February 2017: Hepatobiliary Surgery and Nutrition
https://www.readbyqxmd.com/read/28260927/intrahepatic-cholangiocarcinoma-current-perspectives
#18
REVIEW
Stefan Buettner, Jeroen LA van Vugt, Jan Nm IJzermans, Bas Groot Koerkamp
Intrahepatic cholangiocarcinoma (ICC) is the second most common malignancy arising from the liver. ICC makes up about 10% of all cholangiocarcinomas. It arises from the peripheral bile ducts within the liver parenchyma, proximal to the secondary biliary radicals. Histologically, the majority of ICCs are adenocarcinomas. Only a minority of patients (15%) present with resectable disease, with a median survival of less than 3 years. Multidisciplinary management of ICC is complicated by large differences in disease course for individual patients both across and within tumor stages...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28238581/correlation-of-technetium-99m-macroaggregated-albumin-and-yttrium-90-glass-microsphere-biodistribution-in-hepatocellular-carcinoma-a-retrospective-review-of-pretreatment-single-photon-emission-ct-and-posttreatment-positron-emission-tomography-ct
#19
Paul Haste, Mark Tann, Scott Persohn, Thomas LaRoche, Vasantha Aaron, Thibault Mauxion, Nikhil Chauhan, Matthew R Dreher, Matthew S Johnson
PURPOSE: To evaluate whether technetium-99 ((99m)Tc)-labeled macroaggregated albumin (MAA) can predict subsequent yttrium-90 ((90)Y) distribution and imaging response in patients with hepatocellular carcinoma (HCC). MATERIALS: Retrospective review was performed of records of 83 patients with HCC who underwent (90)Y glass microsphere radioembolization with (99m)Tc-MAA single photon emission computed tomography (SPECT) and (90)Y positron emission tomography (PET)/CT between January 2013 and December 2014...
February 23, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28202430/vespro-an-individual-patient-data-prospective-meta-analysis-of-selective-internal-radiation-therapy-versus-sorafenib-for-advanced-locally-advanced-or-recurrent-hepatocellular-carcinoma-of-the-sarah-and-sirvenib-trials
#20
Val Gebski, Emma Gibbs, Mihir Gandhi, Gilles Chatellier, Aurelia Dinut, Helena Pereira, Pierce Kh Chow, Valérie Vilgrain
BACKGROUND: Untreated advanced hepatocellular carcinoma (HCC) has an overall poor prognosis. Currently there are 2 ongoing prospective randomized controlled trials that are evaluating the efficacy and safety of sorafenib and selective internal radiation therapy (SIRT) with yttrium-90 resin microspheres in patients with advanced HCC. The SorAfenib versus Radioembolisation in Advanced Hepatocellular carcinoma (SARAH; 459 patients) trial is being performed in Europe and the SIRt VErsus SorafeNIB (SIRveNIB; 360 patients) trial in the Asia Pacific region...
February 15, 2017: JMIR Research Protocols
keyword
keyword
33486
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"